Bone health and human immunodeficiency virus infection

Area of Science:

• Bone health and metabolic complications in infectious diseases.
• Pharmacological effects of antiretroviral therapy on bone metabolism.

Background:

• Low bone mineral density (BMD) and increased fracture rates are prevalent in individuals with human immunodeficiency virus (HIV).
• Causes are multifactorial, including traditional risk factors, HIV itself, and antiretroviral treatments.
• Tenofovir, a specific antiretroviral, is associated with significant bone mineral density loss and elevated fracture risk.

Purpose of the Study:

• To review the current understanding of bone health issues in patients with HIV.
• To highlight the role of antiretroviral therapy, specifically tenofovir, in bone loss.
• To identify gaps in knowledge regarding screening and management of low BMD and vitamin D deficiency in this population.

Main Methods:

• Literature review of studies on bone mineral density, osteoporosis, and fractures in HIV-infected individuals.
• Analysis of the impact of antiretroviral agents, with a focus on tenofovir, on bone health.
• Discussion of current guidelines and uncertainties in screening and treatment protocols.

Main Results:

• Emerging evidence links HIV and antiretroviral use to increased fracture risk.
• Tenofovir is implicated in greater bone mineral density reduction compared to other agents.
• Guidelines suggest caution with tenofovir in specific populations, like postmenopausal women.

Conclusions:

• Bone health evaluation and vitamin D assessment are crucial for HIV patients.
• Optimal timing for screening and methods for vitamin D repletion in HIV-positive individuals require further investigation.
• Definitive strategies for managing low bone mineral density and vitamin D deficiency in HIV are needed.